← Russell 3000 cross-section

DMRA Damora Therapeutics, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$1.9bn
Revenue TTM
$8m
Net income TTM
$-263m
Free cash flow
Composite score
Sector rank
#1671

Valuation

P / E
EV / EBITDA
EV / sales
166.1
FCF yield
Earnings yield vs 10-yr
-18.58pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-3,216.2%
EBITDA margin
-3,311.7%
ROE
-50.9%
ROIC
Revenue growth
1,541.0%

Insider activity, last 90 days

Net open-market
$-0.01m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Liquidity and management plans Since inception, the Company has devoted substantially all its efforts to business planning, research and development, recruiting management and technical staff and raising capital, and has financed its operations primarily through the issuance of preferred shares, debt financings, the Company’s initial public offering and sales of Common Stock. Product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. …Damora Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →